Huang Xiaochao, Huang Rizhen, Gou Shaohua, Wang Zhimei, Liao Zhixin, Wang Hengshan
Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China; Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, China.
Pharmaceutical Research Center and School of Chemistry and Chemical Engineering, Southeast University, Nanjing 211189, China; Jiangsu Province Hi-Tech Key Laboratory for Biomedical Research, Southeast University, Nanjing 211189, China.
Bioorg Med Chem. 2017 Sep 1;25(17):4686-4700. doi: 10.1016/j.bmc.2017.07.011. Epub 2017 Jul 8.
Pt(IV) complexes comprising a phenstatin analogue, as dual-targeting Pt(IV) prodrug, were designed and synthesized. They were found not only to carry the DNA binding platinum warhead into the tumor cells, but also to have a small molecular unit to inhibit tubulin polymerization. In vitro evaluation results revealed that Pt(IV) complexes showed better and more potent activity against the test human cancer cells including cisplatin resistant cell lines than their corresponding Pt(II) counterparts. In addition, the Pt(IV) derivative of cisplatin, complex 10, exhibited highly selective inhibition in human cancer cells and displayed no obvious toxicity to two human normal cell lines, respectively. Mechanism study suggested that complex 10 induced cell-cycle arrest at the G2/M phase and caused apoptotic cell death of human lung cancer NCI-H460 cells through the mitochondrial mediated pathway. Moreover, complex 10 effectively inhibited the tumor growth in the NCI-H460 xenograft model.
设计并合成了包含非那他汀类似物的铂(IV)配合物,作为双靶向铂(IV)前药。发现它们不仅能将与DNA结合的铂弹头带入肿瘤细胞,还具有一个小分子单元来抑制微管蛋白聚合。体外评估结果显示,与相应的铂(II)类似物相比,铂(IV)配合物对包括顺铂耐药细胞系在内的受试人类癌细胞表现出更好、更强的活性。此外,顺铂的铂(IV)衍生物配合物10在人类癌细胞中表现出高度选择性抑制,对两种人类正常细胞系分别无明显毒性。机制研究表明,配合物10诱导细胞周期停滞于G2/M期,并通过线粒体介导的途径导致人肺癌NCI-H460细胞凋亡性死亡。此外,配合物10在NCI-H460异种移植模型中有效抑制了肿瘤生长。